AKNE-MYCIN
LOE ApproachingNDATOPICALOINTMENT
Approved
Jan 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AKNE-MYCIN is a topical ointment approved in 1985 for acne treatment. The exact mechanism of action and active ingredient are not publicly specified in available data, but the product name suggests antibiotic or anti-inflammatory properties. It is administered topically and represents a legacy dermatology product.
LOE Approaching
Product faces moderate competitive pressure (30/100) with declining revenue trajectory typical of aging topical agents; expect lean commercial support structures.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
AKNE-MYCIN offers limited career growth opportunities due to its LOE-approaching lifecycle stage and zero linked job openings. Roles available are primarily defensive—managing decline, maintaining compliance, or transitioning to generic/OTC models rather than building brand equity.
Brand ManagerProduct Manager
Worked on AKNE-MYCIN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.